SURPASS-CVOT is the ongoing cardiovascular outcomes trial for tirzepatide. Beyond CV outcomes, tirzepatide has demonstrated improvements in metabolic syndrome markers including blood pressure, lipid profile, hepatic steatosis, and glycemic control.
SURPASS-CVOT will compare tirzepatide vs dulaglutide for CV outcomes in T2D patients with established CV disease. Results expected 2026-2027. Pre-CVOT analyses suggest tirzepatide produces blood pressure reductions of 5-8 mmHg, triglyceride reductions, and significant hepatic steatosis improvements.
This page references peer-reviewed publications listed on PubMed and FDA prescribing information labels. Methodology for source selection is documented on the Methodology page.
Compounded semaglutide + tirzepatide · MD/DO oversight
*12-month plan · flat rate · all titration doses
Or call (949) 818-8000